Alternate Name(s):
Amphadase , Hyalase (Special Access Program)
Classification:
Antidote, extravasations
Original Date:
February 2005
Revised Date:
December 2020
Indications:
- Management of IV extravasation (excluding dopamine and alpha agonist)
Administration:
- SC
Dosage:
Be aware there are 2 concentrations that exist for hyaluronidase. Please double check the vial before mixing. Current brands are listed below, but stock sources can change.
CHEO (Amphadase brand)
- Take 1 mL (150 units) and add to 9 mL of 0.9% NaCl. Resultant solution is 15 units/mL
- Using a 27 gauge needle, administer five 0.2 mL injections (for a total of 15 units) subcutaneously into the extravasation site at the leading edge, changing the needle after each injection
- Use within 1 hour of extravasation for maximal effect
TOH (Hyalase brand)
- Reconstitute the 1500 units ampoule with 1 mL of 0.9% NaCl to obtain 1500 units/mL solution. Draw up 0.1 mL (150 units) into a 10 mL syringe and further dilute with 0.9% NaCl to a final volume of 10 mL. Resultant solution is 15 units/mL
- Using a 27 gauge needle, administer five 0.2 mL injections (for a total of 15 units) subcutaneously into the extravasation site at the leading edge, changing the needle after each injection
- Use within 1 hour of extravasation for maximal effect
Side Effects:
- Local: swelling may occur
- Urticaria, erythema
Reconstitution and Stability:
N/A
Compatibility:
- Incompatible: benzodiazepines, furosemide, phenytoin
Notes:
- Hyaluronidase has an immediate onset of action and a 24-48 hours duration effect
References:
- Extravasation injury from chemotherapy and other non-antineoplastic vesicants. Uptodate. Updated Aug 31. 2017
- Children's Hospital of Eastern Ontario (2014 Revision). Treatment of Infiltrated Vesicant or Irritant Drugs